Patients with CrD-SBC positive for CK7 had significantly worse cancer-specific survival compared to those with CrD-SBC negative for CK7 (HR: 2.72, 95% CI: 1.20–6.17, p=0.016; Fig. 3a), which was confirmed at stage-inclusive bivariable analysis (HR: 2.78, 95% CI: 1.21–6.38, p=0.016). This evidence concerns the gene KRT7 and cancer.